Investors say 'no bueno' to Cytokinetics' complex Royalty deal
Cytokinetics has now all but assured that a buyout is not happening with a $575 million Royalty Pharma funding deal that drew the ire of investors.
Source: fiercebiotech.com
Fady Malik News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Fady Malik. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Fady Malik Today - Breaking & Trending Today
EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
Cytokinetics Inc (NASDAQ:CYTK), a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for muscle diseases, has reported an insider sale according to a recent SEC filing.
Source: yahoo.com
:max_bytes(150000):strip_icc()/GettyImages-1290196714-c8509605980b4c01a74f837e43331439.jpg)
Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug
Cytokinetics Inc. reported positive results Wednesday from a key Phase 3 study of its experimental drug to treat heart disease.
Source: investopedia.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Third Quarter 2023 Conference Call.
Source: insidermonkey.com
EVP Research & Development Fady Malik Sells 2,500 Shares of Cytokinetics Inc
On September 14, 2023, Fady Malik, the Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 2,500 shares of the company.
Source: yahoo.com